Autopsy report · NCT01685489

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

“funding sequestered”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Bastyr University

Sponsor type

University, hospital or other

Conditions

Prostatic Neoplasms

Interventions

Docetaxel, PSK®; Docetaxel, Placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Cannabinoids for Taxane Induced Peripheral Neuropathy
  “Funding being sought” (76% match in meaning)
• IRIS-BioFreedom Cohort in the IRIS-DES Registry
  “Funding issue” (71% match in meaning)
• Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
  “Funding completed.” (70% match in meaning)
• A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
  “Funding issues” (68% match in meaning)
• Smartphone-enabled Health Coaching Intervention for Youth Diagnosed With Major Depressive Disorders
  “New funding required” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.